Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males With a Comparator Arm

Trial Profile

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males With a Comparator Arm

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Setipiprant (Primary)
  • Indications Alopecia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 30 Aug 2018 to 5 Jun 2018.
    • 16 Oct 2017 Planned primary completion date changed from 30 Jun 2018 to 5 Apr 2018.
    • 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top